Te Velde A - Search Results

1

Mobilisation of blood progenitor cells with ifosfamide and etoposide (VP-16) in combination with recombinant human G-CSF (Filgrastim) in patients with malignant lymphomas or solid tumours.

Baars JW, Holtkamp MJ, Nooyen WJ, Walll EV, Te Velde A, Dalesio O, Slaper-Cortenbach IC, Schoot EV, Richel DJ, Gerritsen WR, Schornagel JH, Rodenhuis S. Baars JW, et al. Among authors: te velde a. Anticancer Res. 1996 Sep-Oct;16(5B):3089-95. Anticancer Res. 1996. PMID: 8920773

2

Adjustment of the interface detector (location 71) to the absolute number of mononuclear cells in the peripheral blood: no improvement of the collection efficiency of the Fenwal CS3000 plus during progenitor cell harvests.

Baars JW, Nooyen WJ, van Beers C, Holtkamp MJ, te Velde A, Daleslo O, Slaper-Cortenbach IC, van der Schoot CE, Casteleyn K. Baars JW, et al. Among authors: te velde a. J Clin Apher. 1997;12(2):68-73. doi: 10.1002/(sici)1098-1101(1997)12:2<68::aid-jca3>3.0.co;2-7. J Clin Apher. 1997. PMID: 9263113

3

Phase II study of rhizoxin in squamous cell head and neck cancer. The EORTC Early Clinical Trials Group.

Verweij J, Wanders J, Gil T, Schöffski P, Catimel G, te Velde A, de Mulder PH. Verweij J, et al. Among authors: te velde a. Br J Cancer. 1996 Feb;73(3):400-2. doi: 10.1038/bjc.1996.69. Br J Cancer. 1996. PMID: 8562350 Free PMC article. Clinical Trial.

4

Modulation of phenotypic and functional properties of human peripheral blood monocytes by interleukin-4 (IL-4).

te Velde AA, Yard BA, Klomp JP, de Vries JE, Figdor CG. te Velde AA, et al. Agents Actions. 1989 Jan;26(1-2):199-200. doi: 10.1007/BF02126608. Agents Actions. 1989. PMID: 2785338 Free article. No abstract available.

5

Differential cytostatic activity of monocyte-derived cytokines against human melanoma cells.

te Velde AA, vd Wiel-v Kemenade E, Figdor CG. te Velde AA, et al. Int J Cancer. 1992 Mar 12;50(5):746-51. doi: 10.1002/ijc.2910500514. Int J Cancer. 1992. PMID: 1544709 Free article.

6

Modulation of phenotypic and functional properties of human peripheral blood monocytes by IL-4.

te Velde AA, Klomp JP, Yard BA, de Vries JE, Figdor CG. te Velde AA, et al. J Immunol. 1988 Mar 1;140(5):1548-54. J Immunol. 1988. PMID: 3279117

7

A randomized phase II study with two schedules of the novel indoloquinone EO9 in non-small-cell lung cancer: a study of the EORTC Early Clinical Studies Group (ECSG).

Pavlidis N, Hanauske AR, Gamucci T, Smyth J, Lehnert M, te Velde A, Lan J, Verweij J. Pavlidis N, et al. Among authors: te velde a. Ann Oncol. 1996 Jul;7(5):529-31. doi: 10.1093/oxfordjournals.annonc.a010645. Ann Oncol. 1996. PMID: 8839911 Free article. Clinical Trial.

8

IFN-alpha and IFN-gamma have different regulatory effects on IL-4-induced membrane expression of Fc epsilon RIIb and release of soluble Fc epsilon RIIb by human monocytes.

te Velde AA, Rousset F, Peronne C, De Vries JE, Figdor CG. te Velde AA, et al. J Immunol. 1990 Apr 15;144(8):3052-9. J Immunol. 1990. PMID: 2139077

9

Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 GY) conformal radiotherapy for prostate cancer, using dose-volume histograms.

Boersma LJ, van den Brink M, Bruce AM, Shouman T, Gras L, te Velde A, Lebesque JV. Boersma LJ, et al. Among authors: te velde a. Int J Radiat Oncol Biol Phys. 1998 Apr 1;41(1):83-92. doi: 10.1016/s0360-3016(98)00037-6. Int J Radiat Oncol Biol Phys. 1998. PMID: 9588921

10

Monocyte mediated cytotoxic activity against melanoma.

te Velde AA, Figdor CG. te Velde AA, et al. Melanoma Res. 1992 Jan-Feb;1(5-6):303-9. doi: 10.1097/00008390-199201000-00001. Melanoma Res. 1992. PMID: 1422187 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

158 results

Search Page

Filters